BOOK AN APPOINTMENT >

Kisspeptin For Female Fertility

Kisspeptin Research Protocol Sheet

Female Fertility / IVF Research Context

Compound

Kisspeptin-54

Research Category

Reproductive hormone signaling / IVF oocyte maturation research

Mechanism of Interest

Kisspeptin stimulates GnRH release, which can increase LH and FSH signaling. In fertility research, this has been studied as a way to trigger final oocyte maturation during IVF.

Research-Studied Use

Kisspeptin-54 has been studied as a single timed trigger in medically monitored IVF settings, not as a daily fertility protocol.

Published Research Dosing Context

Human IVF studies have evaluated single subcutaneous kisspeptin-54 administration in weight-based dosing ranges, including 1.6–12.8 nmol/kg and 9.6 nmol/kg protocols.

 

Some high-risk OHSS research studied a second dose 10 hours after the first, but only under clinical trial monitoring.

Timing Used in IVF Research

In published IVF studies, kisspeptin-54 was administered approximately 36 hours before oocyte retrieval, after follicle development was confirmed by ultrasound.

Monitoring Used in Research

Clinical studies included:

     

      • Ultrasound follicle tracking

      • LH, FSH, estradiol, and progesterone monitoring

      • Oocyte retrieval

      • Fertilization and embryo development tracking

      • OHSS safety monitoring

    Important Research Note

    Kisspeptin is not established as an at-home fertility treatment. Published human use has been conducted in controlled IVF environments with reproductive endocrinology oversight.

    Peptabolic Research Disclaimer

    For research and educational purposes only. Not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.

     

    Key source notes: kisspeptin-54 has been studied as a single IVF trigger dose, with trials using subcutaneous weight-based dosing and timed administration before oocyte retrieval. (JCI Insight) A high-risk OHSS study used 9.6 nmol/kg 36 hours before retrieval and studied a second dose 10 hours later in a randomized trial setting. (academic.oup.com)